Literature DB >> 8299669

Dose-dependent absorption and elimination of gamma-hydroxybutyric acid in healthy volunteers.

P Palatini1, L Tedeschi, G Frison, R Padrini, R Zordan, R Orlando, L Gallimberti, G L Gessa, S D Ferrara.   

Abstract

Gamma-hydroxybutyric acid (GHB) is effective in treatment of the alcohol and opiate withdrawal syndromes. Its absorption and disposition kinetics have been studied in 8 healthy male volunteers following oral administration of single doses of 12.5, 25 and 50 mg kg-1. The AUC increased disproportionately with the dose and so the apparent oral clearance decreased significantly as the dose was increased, whereas the terminal half-life and mean residence time increased. The peak plasma concentrations normalised to the lowest dose fell significantly with increasing doses, whilst the corresponding peak times increased. These findings suggest that both the oral absorption and the elimination of GHB are capacity-limited processes. GHB did not bind to significant extent to plasma proteins over the therapeutic concentration range. The pharmacokinetic parameters in healthy volunteers were not significantly different from those previously observed in alcohol-dependent patients with compensated alcoholic liver disease.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8299669     DOI: 10.1007/BF00265954

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  17 in total

1.  Linear and nonlinear kinetics of drug elimination. I. Kinetics on the basis of a single capacity-limited pathway of elimination with or without simultaneous supply-limited elimination.

Authors:  C A van Ginneken; J M van Rossum; H L Fleuren
Journal:  J Pharmacokinet Biopharm       Date:  1974-10

2.  Conversion in vivo of gamma-aminobutyric to gamma-hydroxybutyric acid in the rat.

Authors:  R H Roth; N J Giarman
Journal:  Biochem Pharmacol       Date:  1969-01       Impact factor: 5.858

Review 3.  Gamma-hydroxybutyrate, a possible neurotransmitter.

Authors:  P Vayer; P Mandel; M Maitre
Journal:  Life Sci       Date:  1987-09-28       Impact factor: 5.037

4.  Gas chromatographic determination and pharmacokinetics of 4-hydroxybutrate in dog and mouse.

Authors:  W Pol; E Kleijn; M Lauw
Journal:  J Pharmacokinet Biopharm       Date:  1975-04

5.  Errors in estimating the unbound fraction of drugs due to the volume shift in equilibrium dialysis.

Authors:  J D Huang
Journal:  J Pharm Sci       Date:  1983-11       Impact factor: 3.534

6.  Dose-dependent pharmacokinetics and hypnotic effects of sodium gamma-hydroxybutyrate in the rat.

Authors:  J T Lettieri; H L Fung
Journal:  J Pharmacol Exp Ther       Date:  1979-01       Impact factor: 4.030

7.  Plasma and central nervous system kinetics of gamma-hydroxybutyrate.

Authors:  J S Shumate; O C Snead
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1979-08

8.  Gamma-hydroxybutyric acid for treatment of opiate withdrawal syndrome.

Authors:  L Gallimberti; M Cibin; P Pagnin; R Sabbion; P P Pani; R Pirastu; S D Ferrara; G L Gessa
Journal:  Neuropsychopharmacology       Date:  1993-08       Impact factor: 7.853

9.  Therapeutic gamma-hydroxybutyric acid monitoring in plasma and urine by gas chromatography-mass spectrometry.

Authors:  S D Ferrara; L Tedeschi; G Frison; F Castagna; L Gallimberti; R Giorgetti; G L Gessa; P Palatini
Journal:  J Pharm Biomed Anal       Date:  1993-06       Impact factor: 3.935

10.  Treatment of narcolepsy with gamma-hydroxybutyrate. A review of clinical and sleep laboratory findings.

Authors:  M Mamelak; M B Scharf; M Woods
Journal:  Sleep       Date:  1986       Impact factor: 5.849

View more
  45 in total

1.  Gamma-hydroxybutyrate and ethanol effects and interactions in humans.

Authors:  Dung Thai; Jo Ellen Dyer; Neal L Benowitz; Christine A Haller
Journal:  J Clin Psychopharmacol       Date:  2006-10       Impact factor: 3.153

2.  Mechanistic modeling of monocarboxylate transporter-mediated toxicokinetic/toxicodynamic interactions between γ-hydroxybutyrate and L-lactate.

Authors:  Bridget L Morse; Nisha Vijay; Marilyn E Morris
Journal:  AAPS J       Date:  2014-05-23       Impact factor: 4.009

3.  Brain uptake of the drug of abuse γ-hydroxybutyric acid in rats.

Authors:  Samuel A Roiko; Melanie A Felmlee; Marilyn E Morris
Journal:  Drug Metab Dispos       Date:  2011-10-21       Impact factor: 3.922

4.  Sodium oxybate: a potential new pharmacological option for the treatment of fibromyalgia syndrome.

Authors:  Todd J Swick
Journal:  Ther Adv Musculoskelet Dis       Date:  2011-08       Impact factor: 5.346

Review 5.  Pharmacokinetic and pharmacodynamic principles of illicit drug use and treatment of illicit drug users.

Authors:  D I Quinn; A Wodak; R O Day
Journal:  Clin Pharmacokinet       Date:  1997-11       Impact factor: 6.447

6.  Monocarboxylate Transporter Inhibition with Osmotic Diuresis Increases γ-Hydroxybutyrate Renal Elimination in Humans: A Proof-of-Concept Study.

Authors:  Marilyn E Morris; Bridget L Morse; Gloria J Baciewicz; Matthew M Tessena; Nicole M Acquisto; David J Hutchinson; Robert Dicenzo
Journal:  J Clin Toxicol       Date:  2011-11-10

7.  A Novel Monocarboxylate Transporter Inhibitor as a Potential Treatment Strategy for γ-Hydroxybutyric Acid Overdose.

Authors:  Nisha Vijay; Bridget L Morse; Marilyn E Morris
Journal:  Pharm Res       Date:  2014-12-06       Impact factor: 4.200

8.  Monocarboxylate transporter-mediated transport of gamma-hydroxybutyric acid in human intestinal Caco-2 cells.

Authors:  Wing Ki Lam; Melanie A Felmlee; Marilyn E Morris
Journal:  Drug Metab Dispos       Date:  2009-12-01       Impact factor: 3.922

9.  Pharmacokinetics and pharmacodynamics of γ-hydroxybutyrate in healthy subjects.

Authors:  Matthias E Liechti; Boris B Quednow; Evangelia Liakoni; Dario Dornbierer; Robin von Rotz; Maria Salomé Gachet; Jürg Gertsch; Erich Seifritz; Oliver G Bosch
Journal:  Br J Clin Pharmacol       Date:  2016-02-25       Impact factor: 4.335

Review 10.  Gamma hydroxybutyric acid (GHB) for the treatment of alcohol dependence: a review.

Authors:  Fabio Caputo; Teo Vignoli; Icro Maremmani; Mauro Bernardi; Giorgio Zoli
Journal:  Int J Environ Res Public Health       Date:  2009-06-24       Impact factor: 3.390

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.